Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Charshawn Lahnwong¹,², Siriporn C. Chattipakorn¹,³,⁴ and Nipon Chattipakorn¹,⁴,⁵*

Abstract
Diabetes mellitus currently affects over 350 million patients worldwide and is associated with many deaths from cardiovascular complications. Sodium–glucose co-transporter 2 (SGLT-2) inhibitors are a novel class of antidiabetic drugs with cardiovascular benefits beyond other antidiabetic drugs. In the EMPA-REG OUTCOME trial, empagliflozin significantly decreases the mortality rate from cardiovascular causes (38% relative risk reduction (RRR)), the mortality rate from all-causes (32% RRR) and the rate of heart failure hospitalization (35% RRR) in diabetic patients with established cardiovascular diseases. The possible mechanisms of SGLT-2 inhibitors are proposed to be systemic effects by hemodynamic and metabolic actions. However, the direct mechanisms are not fully understood. In this review, reports concerning the effects of SGLT-2 inhibitors in models of diabetic cardiomyopathy, heart failure and myocardial ischemia from in vitro, in vivo as well as clinical reports are comprehensively summarized and discussed. By current evidences, it may be concluded that the direct effects of SGLT-2 inhibitors are potentially mediated through their ability to reduce cardiac inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ionic dyshomeostasis.

Keywords: Sodium–glucose co-transporter 2 (SGLT-2) inhibitors, Heart, Diabetes mellitus

Background
Diabetes mellitus (DM) currently affects over 350 million patients globally [¹]. The causes of death up to 80% in patients with type 2 DM (T2DM) are associated with cardiovascular diseases [², ³]. Diabetic cardiomyopathy is a progressive disease which affects both cardiac structure and function in diabetic patients. These abnormalities include cardiac hypertrophy, cardiac apoptosis and necrosis, ventricular dilatation and interstitial fibrosis [⁴, ⁵] which consequently leads to both systolic and diastolic dysfunctions [⁶]. Metabolic disturbances, including hyperglycemia, insulin resistance and hyperlipidemia, play an important role in the diabetic cardiomyopathy process by triggering the renin–angiotensin–aldosterone system, altered lipid metabolism, inflammation, oxidative stress, mitochondrial dysfunction and endoplasmic reticulum (ER) stress [⁷]. Chronic exposure to these conditions make heart limited to physiological adaptation and repair capacity.

The sodium–glucose co-transporters (SGLT) are a family of active glucose transporter proteins with two major isoforms, SGLT-1 and SGLT-2 [⁸]. SGLT-1 expression found in the small intestine, liver, lung, kidney and heart, whereas SGLT-2 expression is predominantly found in the kidney [⁹]. SGLT-2 inhibitors are a novel class of antidiabetic drugs which produce glycosuric and natriuretic effects by inhibiting glucose and sodium reabsorption from the proximal convoluted tubules [¹⁰]. Some SGLT-2 inhibitors, including canagliflozin, dapagliflozin and empagliflozin, have been approved for their use in Europe and the USA [¹¹]. Recently, SGLT-2 inhibitors have become the topic of interest due to the benefits in a cardiovascular outcome trial beyond other antidiabetic drugs. The EMPA-REG OUTCOME trial (2010–2015) showed the cardioprotective effect of empagliflozin by significantly lowering the rate of death
from cardiovascular causes [38% relative risk reduction (RRR)], all-cause death (32% RRR) and heart failure hospitalization (HHF) (35% RRR) in T2DM patients with established cardiovascular diseases (CVD) [12]. These benefits of empagliflozin are expected to be class effects with SGLT-2 inhibitors. Several studies also supported this evidence [13–15] as summarized in Table 1. The CANVAS trial (2009–2017) showed canagliflozin significantly reduced the composite of cardiovascular-cause death, nonfatal myocardial infarction (MI) or nonfatal stroke [hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.75–0.97] and HHF (HR 0.67, 95% CI 0.52–0.87) [13]. The CVD-REAL study which reported the cardiovascular effect of SGLT-2 inhibitors compared to other glucose-lowering drugs showed that SGLT-2 inhibitors could significantly decrease the rate of HHF (HR 0.49, 95% CI 0.41–0.57) and all-cause death (HR 0.61, 95% CI 0.51–0.73) [14]. Ongoing cardiovascular trials of SGLT-2 inhibitors include DECLARE-TIMI 58 (dapagliflozin, 2013–2019), VERTIS CV (ertugliflozin, 2013–2019) and RECEDE-CHF (empagliflozin, 2017–2019) may help to confirm this expectation [16–18].

Despite the cardiovascular benefits of SGLT-2 inhibitors, their biological mechanisms leading to cardioprotection are not fully understood. Possible mechanisms are clearly proposed to be systemic effects by hemodynamic actions via natriuresis and metabolic actions via glycosuria [19–23]. Natriuresis results in lowering plasma volume and blood pressure, which are subsequently decreasing cardiac preload and afterload [24–27]. This effect occurs without heart rate changes suggesting the lack of sympathetic stimulation [24, 28]. Empagliflozin also reduces arterial stiffness and vascular resistance in diabetic patients [28, 29]. In renal hemodynamics, empagliflozin attenuates albuminuria and hyperglycemia induced glomerular hyperfiltration, resulting in decreased intraglomerular hypertension [30–32]. The modulation of systemic and renal hemodynamics by SGLT2 inhibitors decreases cardiac workload and improves cardiac function. Glycosuria results in reducing plasma glucose concentration and subsequently decreasing glucotoxicity, a factor which leads to diabetic cardiomyopathy, as evidenced by the improvement of \( \beta \) cell function and insulin sensitivity [33, 34]. Interestingly, one of the benefits of SGLT-2 inhibitors beyond other hypoglycemic drugs is that they do not cause hypoglycemia, since they can enhance endogenous glucose production [33, 34]. The mechanism responsible for this benefit is the increase of plasma glucagon concentration by SGLT-2 inhibitors [33–35]. Dapagliflozin can directly stimulate pancreatic alpha cells for glucagon secretion [35]. Glucagon is known as the key hormone for hepatic glucose production [36, 37], enhances ketogenesis [38, 39] and improves cardiac contractility [40, 41]. Furthermore, SGLT-2 inhibitors can shift metabolism from carbohydrate to lipid [33, 42] and increase ketone body level in both animal and clinical studies [42–44]. The mechanisms responsible for that are potentially from compensatory mechanisms of glucose lowering drugs [45], reducing renal ketone body clearance [46] and enhancing ketone body production by glucagon action [33–35]. Ketone bodies are good energy source in myocardium especially in failing hearts [47, 48]. In addition, ketone bodies are associated with anti-arrhythmia and increasing mitochondrial biogenesis [49, 50]. This is known as the ketone body theory [51]. However, their benefits and mechanisms are still questionable because ketone bodies can precipitate diabetic ketoacidosis, a serious complication of diabetes [46]. Glycosuria also results in weight and fat mass reduction due to stimulation of lipid oxidation compensating for energy loss [52–54]. Both hemodynamic and metabolic actions of SGLT-2 inhibitors potentially work together for improving diabetic cardiomyopathy and finally resulting in cardioprotection as shown in the EMPA-REG OUTCOME trial. However, only systemic mechanisms may be not enough to explain much better cardiovascular benefits of SGLT-2 inhibitors when compared to other glucose-lowering drugs. Their direct cardiac mechanisms, even no SGLT-2 expression in the heart [9, 55, 56], may be the answers for that. Therefore, the objective of this review was to comprehensively summarize reports from in vitro, in vivo and clinical studies regarding the evidence of possible direct mechanisms responsible for cardioprotective effect of SGLT-2 inhibitors, which are independently from their systemic actions.

**Effects of SGLT-2 inhibitors on cardiac structure**

SGLT-2 inhibitors have been shown to improve cardiac histopathologic changes in the diabetic cardiomyopathy models of mice and rats, the heart failure model of zebrafish embryos and also the myocardial ischemic model of rats. These reports are summarized in Table 2. In 2016, Kusaka et al. studied the effect of empagliflozin in genetic prediabetes/metabolic syndrome rat model [57]. After 10 weeks of treatment, empagliflozin significantly reduced left ventricular weight, cardiomyocyte size, cardiac interstitial fibrosis and cardiac interstitial macrophage infiltration. Several reports that studied the effect of empagliflozin in genetic diabetic mouse models also suggested the improvement of cardiac morphologic changes by decreasing the cardiomyocyte cross sectional area, interstitial collagen I and III depositions, interstitial fibrosis and interstitial macrophage infiltration [58, 59]. Lin et al. also reported that empagliflozin could attenuate pericoronary arterial fibrosis and coronary arterial
Table 1 Summary of selected clinical studies reported on the effect of SGLT-2 inhibitors on cardiovascular outcomes

| Model          | n  | Treatment                                                                 | Major findings                                                                 | Interpretation                                                                 | References |
|----------------|----|---------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| T2DM + high CV risk | 7020 | RCTs (EMPA-REG OUTCOME trial); Empagliflozin (10 or 25 mg/days) vs. placebo/PO/3.1 years | ↓ Cardiovascular-cause death (38% RRR) ↓ All-cause death (32% RRR) ↓ HHF (35% RRR) ↔ MI, stroke | Empagliflozin reduced the rate of HHF, death from cardiovascular and/or any causes in T2DM population at high risk for CV events | [12]       |
| T2DM + high CV risk | 10,142 | RCTs (CANVAS trial); Canagliflozin (100 or 300 mg/days) vs. placebo/PO/3.6 years | ↓ Composite of cardiovascular-cause death, nonfatal MI or nonfatal stroke (HR 0.86, 95% CI 0.75–0.97) ↓ HHF (HR 0.67, 95% CI 0.52–0.87) ↔ All-cause death, cardiovascular-cause death, nonfatal MI, nonfatal stroke | Canagliflozin reduced the rate of HHF and composite of death from cardiovascular causes, nonfatal MI or nonfatal stroke in T2DM population at high risk for CV events | [13]       |
| T2DM           | 309,056 | Retrospective observational (CVD-REAL study); SGLT-2 inhibitors vs. glucose-lowering drugs/> 1 year | ↓ HHF (HR 0.49, 95% CI 0.41–0.57) ↓ All-cause death (HR 0.61, 95% CI 0.51–0.73) | SGLT-2 inhibitors reduced all-cause death and HHF compared with other glucose-lowering drugs in T2DM population | [14]       |
| T2DM           | 14,697 | Retrospective observational; SGLT-2 inhibitors vs. DPP-4 inhibitors/2 years | ↓ HHF (HR 0.68, 95% CI 0.54–0.86)                                              | SGLT-2 inhibitors reduced HHF compared with DPP-4 inhibitors in T2DM population | [15]       |

SGLT-2 sodium-glucose co-transporter 2, T2DM type 2 diabetic mellitus, CV cardiovascular, RCTs randomized control trials, vs versus, RRR relative risk reduction, HHF hospitalization for heart failure, MI myocardial infarction, HR hazard ratio, 95% CI 95% confidence interval, DPP-4 dipeptidyl peptidase-4
Table 2  Summary of the effects of SGLT-2 inhibitors on cardiac structure in animal models

| Animal species | Model                                                                 | Drug/dose/route               | Major findings                                                                 | Interpretation                                                                 | References |
|----------------|------------------------------------------------------------------------|------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| Wistar rats    | Streptozotocin-induced diabetic cardiomyopathy                         | Empagliflozin (30 or 10 mg/kg/day)/PO/8 weeks | ↓ Disorganized cell arrays and focal necrosis in dose-dependent manner         | Empagliflozin improved structural changes in the myocardium of streptozotocin-induced diabetic cardiomyopathy rats | [62]       |
| SHR/NDmcrc-p(+/+) rats | Prediabetes/metabolic syndrome                                     | 0.03% empagliflozin/diet/10 weeks | ↓ LV weight and cardiomyocyte size                                             | Empagliflozin improved cardiac hypertrophy and interstitial fibrosis in genetic prediabetic metabolic syndrome rats | [57]       |
| db/db mice     | Diabetes/obesity (diastolic dysfunction and LVH)                       | Empagliflozin (10 mg/kg/days)/PO/5 weeks | ↓ Cardiomyocyte cross sectional area                                            | Empagliflozin improved LVH and myocardial fibrosis in db/db mice               | [59]       |
| db/db mice     | Diabetes/obesity (diastolic dysfunction and LVH)                       | 0.03% empagliflozin/diet/10 weeks | ↓ Cardiac interstitial and pericoronary arterial fibrosis                       | Empagliflozin attenuated cardiovascular remodeling in db/db mice               | [58]       |
| db/db mice     | T2DM/obesity (LV diastolic dysfunctions)                               | Empagliflozin (10 mg/kg/days)/PO/6 weeks | ↔ LV mass, myocardial fibrosis                                                | Empagliflozin attenuated markers of cardiac hypertrophy and remodeling, but not altered cardiac fibrosis in ob/ob mice | [60]       |
| BTBR ob/ob mice | T2DM                                                                  | Dapagliflozin (1 mg/kg/days)/PO/4 weeks | ↓ Infarct size                                                                | Dapagliflozin attenuated cardiac fibrosis in BTBR ob/ob mice                   | [63]       |
| Rats           | High fat diet induced obese-insulin resistance for 4 weeks then I/R injury by LAD ligation | Dapagliflozin (1 mg/kg/days)/PO/4 weeks | ↓ Infarct size                                                                | Dapagliflozin attenuated MI size in pre-diabetic rats with cardiac I/R injury  | [64]       |
| Wistar rats    | MI by LAD ligation in rats                                            | Dapagliflozin (0.1 mg/kg/day)/PO/Start after 1-day infarction for 4 weeks | ↔ Infarct size                                                                | Dapagliflozin attenuated myofibroblast infiltration during post-infarction remodeling in rats | [65]       |
| cmc2::GFP zebrafish embryos | Aristolochic acid induced heart failure                             | Empagliflozin (0.1, 10 μM)/media/3 days | ↓ Morphologic changes in a concentration-dependent manner included unlooping defects, cardiac edema, and deformed cardiac chambers | Empagliflozin improved heart failure morphology and attenuated heart failure markers in zebrafish embryos | [66]       |

SGLT-2 sodium–glucose co-transporter 2, PO per oral, LV left ventricular, LVH left ventricular hypertrophy, SGK1 serum and glucocorticoid-inducible kinase 1, ENaC epithelial Na+ channel, T2DM type 2 diabetic mellitus, Anf atrial natriuretic peptide/factor, β-Mhc beta-myosin heavy chain, p-ERKs phosphorylated extracellular signal-regulated kinase, p-JNKs phosphorylated c-Jun NH2-terminal kinase, I/R ischemic/reperfusion, LAD left anterior descending artery, MI myocardial infarction
thickening [58]. The reduction of cardiac fibrosis was shown to be due to the attenuation of the expression of pro-fibrotic signaling pathway, serum- and glucocorticoid-regulated kinase 1 (SGK1) and epithelial sodium channel (ENaC) [59]. In another genetic diabetic mouse model, empagliflozin was given for a total of 6 weeks [60]. Although there were no significant changes in left ventricular (LV) mass and histologic myocardial fibrosis, the treatment group showed the decrease of cardiac hypertrophy and remodeling markers. Empagliflozin was found to decrease the mRNA expression of hypertrophic fetal genes including atrial natriuretic peptide/factor and betamyosin heavy chain. It also decreased the expression of proteins associated with mitogen-activated protein kinase pathways, including extracellular signal-regulated kinases, c-Jun NH2-terminal kinases and p38, which played an important role in the development of cardiac remodeling [61]. In streptozotocin-induced diabetic cardiomyopathy rats treated with empagliflozin for 8 weeks, the attenuation of disordered cell arrays and focal necrosis was observed in a dose-dependent manner [62]. Furthermore, Ye et al. showed that the treatment of dapagliflozin for 8 weeks decreased myocardial collagen-1 and collagen-3 mRNA levels and percentage of fibrosis in genetic diabetic mice [63]. These reports suggest that the improvement of diabetic cardiomyopathy morphology is potentially to be class effects of SGLT-2 inhibitors.

In addition to the diabetic cardiomyopathy model, SGLT-2 inhibitors were also tested in models of myocardial ischemia and heart failure. We recently demonstrated that by giving dapagliflozin for 4 weeks in high fat diet induced obese-insulin resistance rats and underwent acute ischemic/reperfusion (I/R) injury by left anterior descending artery (LAD) ligation, dapagliflozin could attenuate myocardial infarct size [64]. In chronic MI rat model, Lee et al. investigated the effect of dapagliflozin treatment beginning 1 day after LAD ligation and continued for 4 weeks [65]. They found that dapagliflozin did not alter the size of an infarction, however it could attenuate myofibroblast infiltration and cardiac fibrosis. In 2017, Shi et al. tested the effect of empagliflozin in aristolochic acid induced heart failure in zebrafish embryos [66]. Zebrafish embryos treated with aristolochic acid would develop cardiac hypertrophy, bradycardia and profound cardiac failure within 3 days of age [67]. Pretreatment with empagliflozin showed the improvement of histopathologic changes including unlooping defects, cardiac edema and deformed cardiac chambers in a concentration-dependent manner [66]. Furthermore, empagliflozin could attenuate the expression of heart failure markers including atrial natriuretic peptide and brain natriuretic peptide. In a very recent clinical trial, Januzzi et al. tested the effect of 2-year canagliflozin treatment in 666 elderly T2DM patients [68]. Compared to placebo, treatment with canagliflozin delayed the rise of heart failure biomarkers including serum N-terminal pro-brain natriuretic peptide and high-sensitivity troponin I.

Effects of SGLT-2 inhibitors on cardiac function
SGLT-2 inhibitors have also been shown to improve cardiac function in diabetic cardiomyopathy models and myocardial ischemic models of mice and rats as summarized in Table 3. In genetic diabetic mice, 8-week treatment of dapagliflozin improved ejection fraction (EF) and fractional shortening [63]. It also attenuated the increase in end-systolic volume (ESV), end-diastolic volume (EDV), interventricular septal thickness in systole and diastole. Dapagliflozin also improved the E/A (early/late diastolic) ratio, EF, isovolumic relaxation time (IVRT), deceleration time (DT) and end diastolic wall thickness (EDWT) in a diabetic non-obese mouse model [69]. These reports indicated that dapagliflozin could improve both systolic and diastolic LV function in diabetic mice.

For empagliflozin, a number of reports showed its benefits preferred diastolic function to systolic function [57–60, 62]. In genetic diabetic mice, empagliflozin improved diastolic function as seen by increased septal wall motion and decreased LV filling pressure [59]. It also attenuated vascular dilating dysfunction by ameliorating the impairment of vascular endothelium-dependent relaxation in thoracic aortas [58]. Moreover, empagliflozin has been shown to improve LV diastolic function, both in relaxation and compliance, as evidenced by a decrease in E wave (mitral inflow peak velocity), E wave deceleration time, Tau (time constant for isovolumic relaxation) and end-diastolic pressure–volume relationship [60]. However, LV systolic function was not affected in this report. In a diabetic cardiomyopathy rat model, empagliflozin also improved LV function by the increase of end-systolic pressure (ESP), +dp/dt and −dp/dt (the maximal ascending rate and the maximal descending rate of left ventricular pressure, respectively) and the decrease of end-diastolic pressure–volume relationship [60]. However, in the prediabetic/metabolic syndrome rat model, 10 weeks of empagliflozin treatment, which attenuated LV weight and cardiac interstitial fibrosis, did not significantly improve heart rate, blood pressure, sympathetic activity or baroreceptor function [57].

Electrophysiologically, two recent clinical studies reported the effect of SGLT-2 inhibitors on electrocardiographic parameters in patients with T2DM [68, 70]. Sato et al. retrospectively analyzed changes in indices of ventricular repolarization before and after 0.66-year treatment with SGLT-2 in 46 people with T2DM [70]. They found the heart rate and QTc interval were not changed, but QTc dispersion was significantly decreased,
Table 3 Summary of the effects of SGLT-2 inhibitors on cardiovascular function in animal models

| Animal species | Model | Drug/dose/route | Major findings | Interpretation | References |
|----------------|-------|----------------|----------------|----------------|------------|
| Wistar rats    | Streptozotocin-induced diabetic cardiomyopathy | Empagliflozin (30 or 10 mg/kg/days)/PO/8 weeks | ↑ ESP , + dp/dt and − dp/dt ↓ EDP | Empagliflozin improved LV function in streptozotocin-induced diabetic cardiomyopathy rats | [62] |
| SHR/NDmc-rcp (+/+ ) rats | Prediabetes/metabolic syndrome | 0.03% empagliflozin/diet/7 weeks | ↔ HR, SBP, DBP, locomotor activity, LF-SBP, sBRG and LF/HF ratio of PI | Empagliflozin did not have effect on heart rate, blood pressure, sympathetic activity, or baroreceptor function in genetic prediabetic metabolic syndrome rats | [57] |
| db/db mice    | Diabetes/obesity (diastolic dysfunction and LVH) | Empagliflozin (10 mg/kg/days)/PO/5 weeks | ↑ Septal wall motion ↓ CO, SV, LV filling pressure ↔ EF, FS | Empagliflozin improved septal wall motion and LV filling pressure in db/db mice | [59] |
| db/db mice    | Diabetes/obesity (diastolic dysfunction and LVH) | 0.03% empagliflozin/diet/10 weeks | ↓ Impairment of vascular endothelium-dependent relaxation in thoracic aorta | Empagliflozin attenuated vascular dilating dysfunction in db/db mice | [58] |
| ob/ob mice    | T2DM/metabolic syndrome (LV diastolic dysfunction) | Empagliflozin (10 mg/kg/days)/PO/6 weeks | ↓ E wave, E wave deceleration time, TAU, ESPVR ↔ HR, EF, FS, and ESPVR | Empagliflozin improved LV diastolic function but not systolic function in ob/ob mice | [60] |
| BTBR ob/ob mice | T2DM | Dapagliflozin (1 mg/kg/days)/PO/8 weeks | ↑ E/A ratio and EF ↓ IVRT, DT and EDWT ↔ EDV | Dapagliflozin improved LV function in BTBR ob/ob mice | [63] |
| Seipin knockout (SKO) mice | Diabetic lipodystrophic cardiomyopathy | Dapagliflozin (1 mg/kg/days)/PO/8 weeks | ↑ E/A ratio and EF ↓ IVRT, DT and EDWT ↔ EDV | Dapagliflozin improved both systolic and diastolic LV function in SKO mouse | [69] |
| Rats | High fat diet induced obese-insulin resistance for 4 weeks then I/R injury by LAD ligation | Dapagliflozin (1 mg/kg/days)/PO/4 weeks | Before I/R injury ↑ E/A ratio and EF ↓ HR, IVRT, DT and EDWT During I/R injury ↑ Time to 1st VT/VF onset ↓ Anhythmia score ↑ Gap junction protein connexin 43 expression ↔ Number of VT/VF and VT/VF incidence ↑ ESP, SV, EF and SW ↓ HR, ESP, SV, EDV | Dapagliflozin improved both systolic and diastolic LV function and heart rate variability in pre-diabetic rats | [64] |
| Wistar rats | MI by LAD ligation in rats | Dapagliflozin (0.1 mg/kg/days)/PO/Start after 1-day infarction for 4 weeks | ↑ Maximal rate of LV + dp/dt and − dp/dt | Dapagliflozin improved cardiac function during post-infarction remodeling in rats | [65] |

SGLT-2 sodium-glucose co-transporter 2, PO per oral, ESP end-systolic pressure, EDV end-diastolic pressure, + dp/dt maximal ascending rate of left ventricular pressure, LV left ventricular, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, LF low frequency, sBRG spontaneous baroreceptor reflex gain, HF high frequency, PI pulse interval, LVH left ventricular hypertrophy, CO cardiac output, SV stroke volume, EF ejection fraction, FS fractional shortening, T2DM type 2 diabetic mellitus, E wave mitral inflow peak velocity, Tau time constant for isovolumic relaxation, ESPVR end-systolic pressure–volume relationship, EDV end-diastolic pressure–volume relationship, LV left ventricular volume, IVSs interventricular septal thickness in systole, IVSd interventricular septal thickness in diastole, E/A early/late diastolic, IVRT isovolumic relaxation time, DT deceleration time, EDWT end diastolic wall thickness, I/R ischemic/reperfusion, LAD left anterior descending artery, VT ventricular tachycardia, VF ventricular fibrillation, SW stroke work, MI myocardial infarction
suggesting that SGLT-2 inhibitors could reverse ventricular repolarization heterogeneity in T2DM patients. However, inconsistent findings exist. Januzzi et al. demonstrated the negative results from a randomized control trial which tested the effect of a 2-year canagliflozin treatment compared to placebo in 666 elderly T2DM patients [68]. They found that canagliflozin did not change any electrocardiographic parameters including PR interval, QRS interval, QT/QTc or RR intervals. Therefore, more clinical trials are required to assess the effects of SGLT-2 inhibitors on the cardiovascular function.

In addition to the diabetic cardiomyopathy models, SGLT-2 inhibitors also improved cardiac function in models of myocardial ischemia. In 2018, Tanajak et al. tested the dapagliflozin effect in obese-insulin resistance rats with I/R injury [64]. Before I/R injury operation, 4-week dapagliflozin treatment already showed the improvement of E/A ratio, EF, IVRT, DT and EDWT which referred to both systolic and diastolic LV function. Furthermore, during I/R injury, rats treated with dapagliflozin gave the increase of time to the first ventricular tachycardia/fibrillation onset, the increase of gap junction protein connexin 43 expression, the decrease of arrhythmia score and the improvement of EF, stroke volume, ESP, EDP, ESV and EDV. Similar results were found in Wistar rats with MI treated with dapagliflozin for 4 weeks in which the improvement of cardiac function as evidenced by increasing the maximal rate of LV +dP/dt and −dP/dt were observed [65]. Based on the EMPA-REG OUTCOME trial, there were no significant differences in the rates of MI between the placebo and treatment groups [12]. However, as evidenced from animal studies, SGLT-2 inhibitors could potentially exert beneficial effects to decrease the severity of MI both structural and function. Future clinical studies are needed to warrant these findings from basic reports.

**Potential mechanisms of SGLT-2 inhibitors responsible for cardioprotection**

**SGLT-2 inhibitors on cardiac inflammation**

Cardiac inflammation is one of the mechanisms that leads to diabetic cardiomyopathy in diabetic patients [71–73]. Evidence shows that SGLT-2 inhibitors, together with systemic effects, could directly decrease cardiac inflammation. These effects of SGLT-2 inhibitors on cardiac inflammation are summarized in Table 4. In the genetic prediabetes/metabolic syndrome rat model, 10 weeks of empagliflozin treatment significantly reduced cardiac interstitial macrophage infiltration [57]. Empagliflozin could also attenuate cardiac macrophage infiltration by decreasing cell numbers in the genetic diabetes/obesity mouse model [58]. Lee et al. also reported the improvement of cardiac inflammation in Wistar rats with acute phase of MI treated with dapagliflozin for 2 days [65]. They revealed that dapagliflozin decreased inflammatory cytokines mRNA levels including IL-1β and IL-6, increased anti-inflammatory cytokine mRNA levels including IL-10, and also increased the M2/M1 phenotype macrophage ratio. Since M1 is pro-inflammatory phenotype of macrophage, whereas M2 is anti-inflammatory one [74], these findings indicated that dapagliflozin promotes macrophage polarization toward an anti-inflammatory phenotype. Furthermore, empagliflozin could attenuate the myocardial expression of pro-inflammatory genes including cyclooxygenase-2 and interleukin-1β (IL-1β) in a heart failure model of zebrafish embryos [66]. All of these findings suggest that empagliflozin can reduce cardiac inflammation in diabetic cardiomyopathy, myocardial ischemia and heart failure models. However, we cannot conclude whether these benefits are from systemic and/or direct cardiac effects. More in vitro studies are required to explore its direct role independently from systemic one.

Interestingly, a recent study revealed the direct mechanism of SGLT-2 inhibitors on cardiac inflammation reduction through the reduction of cardiac nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflamasome [63]. The NLRP3 inflamasome is an interleukin-1β family cytokine-activating multi-protein signaling complex upregulated in the heart and associated with cardiac inflammation in T2DM, which leads to subsequent diabetic cardiomyopathy [75–79]. NACHT, LRR and PYD domains-containing protein 3 (NALP-3), the protein encoded by the NLRP3 gene, together with apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) form a protein complex activating caspase-1, which subsequently leads to stimulating the production of pro-inflammatory cytokines [72, 73]. Ye et al. tested the effect of 8-week dapagliflozin treatment on cardiac inflammation in genetic diabetic mice and found that dapagliflozin decreased the levels of myocardial mRNA associated with NLRP3 inflamasome and pro-inflammatory cytokines including NALP-3, ASC, caspase-1, IL-1β, IL-6 and TNFα [63]. To rule out systemic effects, they further performed in vitro experiment by incubating mouse cardiofibroblasts in media containing dapagliflozin for 16 h. Interestingly, dapagliflozin also attenuated NALP-3, ASC, caspase-1 and IL-1β mRNA levels in a dose-dependent manner [63]. Since SGLT-2 does not exist in cardiac tissue [9, 55, 56], these results suggested that these effects are unrelated from SGLT-2 and glucose reducing effects of dapagliflozin.

**SGLT-2 inhibitors on cardiac oxidative stress**

Oxidative stress plays an important role in the pathogenesis of cardiac hypertrophy and remodeling
Table 4 Summary of the effects of SGLT-2 inhibitors on cardiac inflammation in animal models

| Animal species | Model | Drug/dose/route | Major findings | Interpretation | References |
|----------------|-------|----------------|----------------|----------------|------------|
| SHR/NDmc1-cp (+/+) rats | Prediabetes/metabolic syndrome | 0.03% empagliflozin/diet/10 weeks | ↓ Cardiac interstitial macrophage infiltration | Empagliflozin attenuated cardiac macrophage infiltration in genetic prediabetic metabolic syndrome rats | [57] |
| db/db mice | Diabetes/obesity (diastolic dysfunction and LVH) | 0.03% empagliflozin/diet/10 weeks | ↓ Cardiac macrophage infiltration | Empagliflozin attenuated cardiac macrophage infiltration in db/db mice | [58] |
| BTBR ob/ob mice | T2DM | Dapagliflozin (1 mg/kg/days)/PO/8 weeks | ↓ NALP-3, ASC, caspase-1, IL-1β, IL-6 and TNFα expressions | Dapagliflozin attenuated NLRP3 inflammasome and inflammatory markers in BTBR ob/ob mice | [63] |
| BTBR ob/ob mice | In vitro cardiofibroblast culture | Dapagliflozin (0.1–0.5 μM)/media/16 h | ↓ NALP-3, ASC, caspase-1 and IL-1β expressions in dose dependent manner | Dapagliflozin attenuated NLRP3 inflammasome and inflammatory markers in cardiofibroblasts of BTBR ob/ob mice. These effects are independent from SGLT-2 and glucose reducing effects of dapagliflozin | [63] |
| Wistar rats | MI by LAD ligation in rats | Dapagliflozin (0.1 mg/kg/days)/PO/Start after 1–day infarction for 2 days | ↑ M2/M1 phenotype macrophage ratio and IL-10 mRNA level ↓ IL-1β and IL-6 mRNA levels | Dapagliflozin promoted macrophages toward anti-inflammatory phenotype, increased anti-inflammatory cytokine and attenuated inflammatory cytokines in rats with acute stage of MI | [65] |
| cmic2:GFP zebrafish embryos | Aristolochic acid induced heart failure | Empagliflozin (0.1, 10 μM)/media/3 days | ↓ Cox-2, IL-1β expressions | Empagliflozin attenuated pro-inflammatory genes in heart failure zebrafish model | [66] |

SGLT-2 sodium–glucose co-transporter 2, LVH left ventricular hypertrophy, T2DM type 2 diabetic mellitus, NALP-3 NACHT, LRR and PYD domains-containing protein 3, ASC apoptosis-associated speck-like protein containing a caspase recruitment domain, IL interleukin, TNFα tumor necrosis factor α, NLRP3 nucleotide-binding oligomerization domain-like receptor 3, MI myocardial infarction, LAD left anterior descending artery, Cox-2 cyclooxygenase-2
SGLT-2 inhibitors have been shown to act as antioxidants by decreasing cardiac oxidative stress, independently from glucose lowering effects, as evidence summarized in Table 5. In genetic prediabetes/metabolic syndrome rat model, 10 weeks of empagliflozin treatment significantly reduced superoxide levels in cardiac tissues [57]. This report showed the reduction of cardiac hypertrophy and interstitial fibrosis although no blood pressure reduction or improvement of cardiac autonomic dysfunction. Therefore, these cardioprotective effects have been attributed to the lowering of cardiac oxidative stress and inflammation. In a genetic diabetic mouse model, 10-week empagliflozin treatment could decrease cardiac and aortic superoxide levels [58]. In a diabetes/obesity mouse model, Habibi et al. showed empagliflozin (10 mg/kg/days) did not alter the levels of cardiac nitrotyrosine, advanced glycation end products (AGEs) and receptors for AGEs (RAGEs) [59]. In aortic tissues of diabetic cardiomyopathy rats, empagliflozin treatment with high dose (30 mg/kg/days) significantly decreased AGEs and RAGEs levels but was unchanged in the low dose (10 mg/kg/days) treatment group [83]. Therefore, a high dose of empagliflozin treatment is required for oxidative stress reduction.

For a model of acute myocardial ischemia, we previously demonstrated that dapagliflozin attenuated malondialdehyde in the cardiac ischemic area of obese-insulin resistant rats with I/R injury [64]. In a chronic MI model of rats, Lee et al. showed that dapagliflozin acted as an antioxidant and mediated M2 macrophage polarization through the signal transducer and activator of the transcription 3 (STAT3) mediated pathway [65]. Antioxidants, the reactive oxygen and nitrogen species (RONS) scavengers, are known to increase protein homologous protein (CHOP), a subsequent protein of the apoptotic pathway, can stimulate the caspase 8, 12, and 10 [65]. Once ERS occurred, caspase-12 mediated apoptosis, which is a unique apoptosis pathway of cardiac cells [90]. Inhibitions of ERS could attenuate myocardial apoptosis and diabetic cardiomyopathy development in streptozotocin-induced diabetic rats [91, 92]. In response to ERS, glucose-regulated protein 78 (GRP78), a major ER chaperone protein, is activated and plays a vital role in detecting the abnormal proteins [93]. Once ERS occurred, caspase-12-mediated apoptosis, which is a unique apoptosis pathway of ER, is activated [94, 95]. Then, CCAAT-enhancer-binding protein homologous protein (CHOP), a subsequent protein of the apoptotic pathway, can stimulate the caspase protein in the cytosol, leading to apoptosis [96]. CHOP can be activated by the over-transcription of activating transcription factor 4 (ATF4), tumor necrosis factor receptor-associated factor 2 (TRAF2) and X-box binding protein 1 (XBP1) [97, 98]. It has been shown that empagliflozin decreased all of mRNA and protein expressions associated with ERS including GRP78, CHOP, Caspase-12, ATF4, TRAF2 and XBP1 [62]. Interestingly, these beneficial effects are in a dose-dependent manner. Thus, another role of empagliflozin in protection against diabetic cardiomyopathy is by attenuating cardiomyocyte apoptosis through inactivating the ERS pathway. However, inconsistent findings exist. A report by Hammad et al. demonstrated that empagliflozin (10 mg/kg/days) did not alter the protein expression of the antiapoptotic molecule Bcl-2 and the pro-apoptotic protein Bax in diabetic mice [60]. These inconsistent findings could be due to different doses of drug used;
### Table 5 Summary of the effects of SGLT-2 inhibitors on cardiac oxidative stress in animal models

| Animal species       | Model                          | Drug/dose/route                  | Major findings                                      | Interpretation                                                                 | References |
|----------------------|--------------------------------|----------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------|------------|
| SHR/NDmcr-cp (+/+) rats | Prediabetes/metabolic syndrome | 0.03% empagliflozin/diet/10 weeks | ↓ Cardiac superoxide level                           | Empagliflozin attenuated cardiac oxidative stress in genetic prediabetic metabolic syndrome rats | [57]       |
| db/db mice           | Diabetes/obesity (diastolic dysfunction and LVH) | Empagliflozin (10 mg/kg/days)/PO/5 weeks | ↔ Cardiac nitrotyrosine level ↔ AGES and RAGEs expressions | Empagliflozin had no effect on myocardial oxidative/nitrosative stress in db/db mice | [59]       |
| db/db mice           | Diabetes/obesity (diastolic dysfunction and LVH) | 0.03% empagliflozin/diet/10 weeks | ↓ Cardiac and aortic superoxide levels               | Empagliflozin attenuated cardiovascular oxidative stress in db/db mice          | [58]       |
| Rats                 | High fat diet induced obese-insulin resistance for 4 weeks then I/R injury by LAD ligation | Dapagliflozin (1 mg/kg/days)/PO/4 weeks | ↓ Malondialdehyde level in ischemic area            | Dapagliflozin attenuated cardiovascular oxidative stress in pre-diabetic rats with cardiac I/R injury | [64]       |
| Wistar rats          | MI by LAD ligation in rats     | Dapagliflozin (0.1 mg/kg/day)/PO/ Start after 1-day infarction for 2 days | ↓ Cardiac superoxide and nitrotyrosine levels ↑ STAT3 activation | Dapagliflozin attenuated cardiac oxidative/nitrosative stress and increased RONS-dependent STAT3-mediated pathway in rats with acute stage of MI | [65]       |
| Wistar rats          | Ex vivo Isolated hearts after 3-day infarction by LAD ligation | Dapagliflozin (10 μM)/media/1 h | ↑ STAT3 activation ↑ IL-10 protein level              | Dapagliflozin activated RONS-dependent STAT3-mediated pathway independently from its SGLT-2 and glucose lowering effects | [65]       |

**SGLT-2** sodium–glucose co-transporter 2, **LVH** left ventricular hypertrophy, **PO** per oral, **AGES** advanced glycation end products, **RAGEs** receptors for AGES, **I/R** ischemic/reperfusion, **MI** myocardial infarction, **LAD** left anterior descending artery, **STAT3** signal transducer and activator of transcription 3, **RONS** reactive oxygen and nitrogen species
empagliflozin treatment at a low dose might not show an improvement [59, 83]. Future studies using a higher dose of empagliflozin treatment should be investigated in vivo to explore its role on an apoptotic protein expression in diabetic cardiomyopathy model.

In myocardial I/R injury model, it has been shown that treatment with dapagliflozin for 4 weeks in obese-insulin resistant rats attenuated Bax/Bcl-2 ratio and cleaved caspase 3 level when these rats underwent I/R injury [64]. By current evidences, SGLT-2 inhibitors seem to attenuate apoptotic myocardial cells in diabetic cardiomyopathy and MI, however more studies are required to explore their roles on cardiac apoptosis.

### SGLT-2 inhibitors on cardiac mitochondrial function

Mitochondria are important to maintain physiological cardiac function due to their roles in energy production, calcium homeostasis and ROS production [99]. Mitochondrial dysfunction is found to be associated with the pathological progression of diabetic cardiomyopathy [100]. Impaired mitochondrial function and dynamics are observed in diabetic patients and leads to myocardial contractile dysfunction [101]. Several reports showed the attenuation of mitochondrial dysfunction by SGLT-2 inhibitor treatment [59, 64].

In a genetic diabetic mouse model, empagliflozin has been shown to attenuate ultrastructural anomalies of inter-myofibrillar mitochondria including disorganized appearance of sarcomeres, reduced matrix electron density, loss of cristae and mitochondrial fragmentation [59]. In obese-insulin resistant rats treated with dapagliflozin for 4 weeks before undergoing cardiac I/R injury, dapagliflozin attenuated the increase of mitochondrial ROS production, depolarization and mitochondrial swelling [64]. The mitochondrial morphology was also improved by attenuating mitochondrial fragmentation, loss of cristae and fusion of cristae. For mitochondrial biogenesis, dapagliflozin increased the protein expressions of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) and carnitine palmitoyltransferase 1 (CPT1), which were essential proteins for the regulation of cardiac mitochondrial fatty acid oxidation [102, 103]. The expression of complex I of the electron transport chain was also increased by dapagliflozin treatment, suggesting its role in restoring the reduction of cardiac energy metabolism during cardiac I/R injury [64].

It is known that mitochondria are dynamic organelles with the balance of continual fission (division) and fusion (joining) [104]. These cycles maintain functional mitochondria by removing damaged mitochondria and facilitating apoptosis when cells are exposed to stress [105]. Dynamin-related protein 1 (DRP1) plays role in constriction of the membrane during fission whereas mitofusin 2 (MFN2) and optic atrophy 1 (OPA1) support fusion of the outer and inner membranes, respectively [100]. It has been shown that an inhibition of cardiac mitochondrial fission could protect the heart during myocardial I/R injury and cardiac arrest [106, 107]. Recently, we have demonstrated that a 4-week treatment with dapagliflozin attenuated the increase of cardiac mitochondrial fission

---

### Table 6 Summary of the effects of SGLT-2 inhibitors on cardiac apoptosis in animal models

| Animal species | Model | Drug/dose/route | Major findings | Interpretation | References |
|----------------|-------|----------------|----------------|----------------|------------|
| Wistar rats    | Streptozotocin-induced diabetic cardiomyopathy | Empagliflozin (30 or 10 mg/kg/days)/PO/8 weeks | ↓ Apoptotic cells | Empagliflozin, in dose-dependent manner, attenuated cardiomyocyte apoptosis by suppressing the endoplasmic reticulum stress pathway in streptozotocin-induced diabetic cardiomyopathy rats | [62] |
| ob/ob mice     | T2DM/obesity (LV diastolic dysfunctions) | Empagliflozin (10 mg/kg/days)/PO/6 weeks | ↔ Bcl2 and Bax levels | Empagliflozin had no effect on apoptotic protein expressions in ob/ob mice | [60] |
| BTBR ob/ob mice | T2DM   | Dapagliflozin (1 mg/kg/days)/PO/8 weeks | ↓ Apoptotic cells | Dapagliflozin attenuated cardiomyocyte apoptosis in BTBR ob/ob mice | [63] |
| Rats           | High fat diet induced obese-insulin resistance for 4 weeks then I/R injury by LAD ligation | Dapagliflozin (1 mg/kg/days)/PO/4 weeks | ↓ Bax/Bcl-2 ratio | Dapagliflozin attenuated apoptotic protein expressions in pre-diabetic rats with cardiac I/R injury | [64] |

SGLT-2: sodium–glucose co-transporter 2, PO per oral, GRP78 glucose-regulated protein 78, CHOP CCAAT-enhancer-binding protein homologous protein, ATF4 activating transcription factor 4, TRAF2 tumor necrosis factor receptor-associated factor 2, XBP1 X-box binding protein 1, T2DM type 2 diabetic mellitus, LV left ventricular, Bcl-2 B-cell chronic lymphocytic leukemia/lymphoma-2, X Box Bcl-2-associated X, I/R ischemic/reperfusion, LAD left anterior descending artery.
and the decrease of mitochondrial fusion as evidenced by decreased DRP1 and increased MFN2 and OPA1 expressions in obese-insulin resistant rats undergoing cardiac I/R injury [64]. The improvement of mitochondrial dynamics observed in this study, together with the improvement of mitochondrial function, morphology, ROS production, biogenesis and protein expressions could be the mechanisms responsible for smaller infarct size with dapagliflozin treatment compared to placebo. However, these benefits are still unclear whether they are from direct cardiac and/or systemic effects. More studies are needed to explore its direct role on the heart.

**SGLT-2 inhibitors on cardiac ionic homeostasis**

Cardiac Ca\(^{2+}\) and Na\(^{+}\) homeostasis plays an important role in maintaining physiologic cardiac function, including rhythm and contraction [108, 109]. Intracellular Na\(^{+}\) and Ca\(^{2+}\) loading has been observed in diabetic hearts, particularly in heart failure [110–112]. Reduction of myocardial intracellular Na\(^{+}\) concentration by inhibition of Na\(^{+}/Ca^{2+}\) or Na\(^{+}/H^{+}\) exchangers improves heart failure and cardiac hypertrophy [113–115]. SGLT-2 inhibitors have been shown to improve cardiac Na\(^{+}\) and Ca\(^{2+}\), as evidence summarized in Table 7. Baartscheer and colleagues demonstrated the direct myocardial effects of empagliflozin on Na\(^{+}\) and Ca\(^{2+}\) concentration alteration, independent from SGLT-2 activity [116]. In isolated ventricular myocytes from rabbits and rats incubated with empagliflozin for 3 h, empagliflozin decreased cytoplasmic Na\(^{+}\) ([Na\(^{+}\)]\(_{c}\)) and Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_{c}\)) and also increased mitochondrial Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_{m}\)). These effects were similar to the effect of Na\(^{+}/H^{+}\) exchange (NHE) inhibitor [110]. These findings were confirmed in cells pre-treated with cariporide, a strong NHE inhibitor, in which the results showed that empagliflozin had very little effect on the [Na\(^{+}\)]\(_{c}\) of these cells. Therefore, despite no SGLT-2 expression in the heart [9, 55, 56], empagliflozin could have cardiac effects by decreasing myocardial [Na\(^{+}\)]\(_{c}\) and [Ca\(^{2+}\)]\(_{c}\) and increasing [Ca\(^{2+}\)]\(_{m}\) through the inhibition of NHE directly. Moreover, Liu and O’Rourke demonstrated that high [Na\(^{+}\)]\(_{c}\) could cause low [Ca\(^{2+}\)]\(_{m}\) through its efflux via mitochondrial Na\(^{+}/Ca^{2+}\) exchanger (NCX) [117]. Increasing [Ca\(^{2+}\)]\(_{m}\) could prevent sudden death in a swine heart failure model [113]. Taken together, SGLT-2 inhibitors directly inhibited myocardial NHE and consequently decreased the cytoplasmic Na\(^{+}\) level, leading to increased mitochondrial Ca\(^{2+}\) level and decreased cytoplasmic Ca\(^{2+}\) level through mitochondrial NCX activity. In addition, it has been shown that empagliflozin improved LV diastolic function by increasing sarcoplasmic endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA2a) activity in genetic diabetic mice [60]. Consistent with this report, Joubert et al. also showed that dapagliflozin increased SERCA2a function in a diabetic lipodystrophic mouse model [69]. SERCA2a is an important calcium handling protein which regulates cardiac contractility via Ca\(^{2+}\) reuptake into sarcoplasmic reticulum [118]. Decreased SERCA2a activity can cause abnormal Ca\(^{2+}\) handling and a contractile state, leading to cardiac contractile dysfunction [119]. All of these findings indicate that the improvement of cardiac calcium handling of SGLT-2 inhibitors through these mechanisms could be responsible for the protective effect in heart failure observed in the EMPA-REG OUTCOME trial.

Table 7 Summary of the effects of SGLT-2 inhibitors on cardiac ionic homeostasis in animal models

| Animal species | Model | Drug/dose/route | Major findings | Interpretation | References |
|----------------|-------|----------------|----------------|---------------|-------------|
| Rabbits and rats | In vitro isolated ventricular myocytes | Empagliflozin (1 μmol/l)/media/3 h | ↓ Myocardial [Na\(^{+}\)]\(_{c}\), and [Ca\(^{2+}\)]\(_{c}\) <br>↑ Myocardial [Ca\(^{2+}\)]\(_{m}\) <br>These effects were strongly reduced after pre-treated with NHE inhibitor | Empagliflozin has cardiac effects by decreasing myocardial cytoplasmic [Na\(^{+}\)], and [Ca\(^{2+}\)], and increasing [Ca\(^{2+}\)]\(_{m}\) through inhibition of NHE directly | (116) |
| ob/ob mice | T2DM/obesity (LV diastolic dysfunctions) | Empagliflozin (10 mg/kg/days)/PO/6 weeks | ↑ SERCA2a/PLN ratio, PLN phosphorylation | Empagliflozin enhances SERCA2a activity leading to improve cardiac contractile dysfunction in ob/ob mice | (60) |
| Seipin knockout (SKO) mice | Diabetic lipodystrophic cardiomyopathy | Dapagliflozin (1 mg/kg/days)/PO/8 weeks | ↑ SERCA2a/PLN ratio | Dapagliflozin enhances SERCA2a activity leading to improve cardiac contractile dysfunction in SKO mice | (69) |

[Na\(^{+}\)]\(_{c}\), cytoplasmic Na\(^{+}\) concentration, [Ca\(^{2+}\)]\(_{c}\), cytoplasmic Ca\(^{2+}\) concentration, [Ca\(^{2+}\)]\(_{m}\), mitochondrial Ca\(^{2+}\) concentration, NHE Na\(^{+}/H^{+}\) exchange, T2DM type 2 diabetic mellitus, LV left ventricular, PO per oral, SERCA2a sarcoplasmic endoplasmic reticulum calcium (Ca\(^{2+}\)) ATPase, PLN phospholamban
Conclusions and perspectives
The cardioprotection of SGLT-2 inhibitors has been demonstrated in models of diabetic cardiomyopathy, heart failure and myocardial ischemia. They are seen to be effective by improving cardiac morphologic changes including cardiac hypertrophy, interstitial fibrosis, heart failure and myocardial infarct size. They also improve both systolic and diastolic LV function in diabetic cardiomyopathy and prevent cardiac arrhythmia in cardiac I/R injury. Potential mechanisms responsible for the cardioprotective effects of SGLT-2 inhibitors are through direct and systemic effects which are summarized in Fig. 1. Their systemic effects are modulated by hemodynamic actions via natriuresis and metabolic actions via glycosuria. The direct effects of SGLT-2 inhibitors could potentially mediate through their abilities to attenuate cardiac inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ionic dyshomeostasis.

Focus on The EMPA-REG OUTCOME trial, empagliflozin decreased the rate of death from cardiovascular causes and HHF in T2DM patients with established CVD [12]. The mechanisms of SGLT-2 inhibitors responsible for these benefits could be due to their systemic as well as direct cardiac effects. SGLT-2 inhibitors can modify risk factors of major cardiovascular events including diabetes and hypertension via lowering blood glucose and blood pressure, respectively. They also directly attenuate cardiac inflammation, oxidative stress [63, 65] which lead to improving both cardiac structure and function, and finally result in decreased mortality rate from cardiovascular causes. For reducing HHF, natriuretic effect of SGLT-2 inhibitors results in lowering plasma volume and blood pressure, which are subsequently decreasing cardiac preload and afterload [24–26]. SGLT-2 inhibitors also directly improve cardiac calcium handling via inhibiting myocardial NHE which subsequently decrease intracellular Na⁺ and Ca²⁺ loading mostly found in heart failure [116]. Therefore, cardiac contractility and cardiac output could be improved in heart failure patients as observed in clinical trials [12–15].

![Fig. 1 Potential mechanisms responsible for cardioprotective effect of SGLT-2 Inhibitors. From current evidence from both in vitro or ex vivo experiments, SGLT-2 inhibitors have been demonstrated that they could have direct cardiac effects on inflammation [63], oxidative stress [65], and ionic dyshomeostasis [116]. Although the effects of SGLT-2 inhibitors on the attenuation of apoptosis and mitochondrial dysfunction could be direct cardiac effects [59, 62, 64], they have not been proved by either in vitro or ex vivo experiments. Italic indicates the mechanisms have not been proved by either in vitro or ex vivo experiments. SGLT-2 sodium–glucose co-transporter 2, NLRP3 nucleotide-binding oligomerization domain-like receptor 3, IL interleukin, STAT3 signal transducer and activator of transcription 3, ERS endoplasmic reticulum stress, Bcl-2 B cell chronic lymphocytic leukemia/lymphoma-2, Pax Bcl-2-associated X, PGC1-α peroxisome proliferator-activated receptor gamma coactivator 1-alpha, CPT1 carnitine palmitoyltransferase 1, ROS reactive oxygen species, NHE Na⁺/H⁺ exchange, [Na⁺], cytoplasmic Na⁺ concentration, [Ca²⁺], cytoplasmic Ca²⁺ concentration, [Ca²⁺]m mitochondrial Ca²⁺ concentration, SERCA2a sarcoplasmic endoplasmic reticulum Ca²⁺-ATPase, I/R ischemic/reperfusion.](image-url)
Despite these growing number of reports, the cardioprotective effects in some respects such as cardiac apoptosis and mitochondrial dysfunctions are still unclear whether they are the direct effects or systemic effects of SGLT-2 inhibitors. More studies of heart failure and myocardial ischemic models are required to investigate the roles of SGLT-2 inhibitors on the heart. Although SGLT-2 does not exist in the myocardium [9, 55, 56], Park et al. reported that endothelial cells of porcine coronary artery exposed to high glucose upregulated SGLT-2 expression despite no expression in normal condition [120]. Even the role of SGLT-2 on vessels has not been understood yet. It has been shown that chronic treatment of SGLT-2 inhibitors in a diabetic mouse model attenuated vascular relaxation dysfunction and atherosclerosis in aorta and coronary artery [58, 121, 122]. More studies investigating the roles of SGLT-2 inhibitors on the heart are needed to warrant their use in the future.

Abbreviations

[Ca\(^{2+}\)_c]: cytoplasmic Ca\(^{2+}\) concentration; [Ca\(^{2+}\)_m]: mitochondrial Ca\(^{2+}\) concentration; [Na\(^+\)_c]: cytoplasmic Na\(^+\) concentration; +dp/dt: the maximal ascending rate of left ventricular pressure; −dp/dt: the maximal declining rate of left ventricular pressure; AGES: advanced glycation end products; ASC: apoptosis-associated speck-like protein containing a caspase recruitment domain; ATF4: activating transcription factor 4; CHOP: CCAAT-enhancer binding protein homologous protein; CPT1: carnitine palmitoyltransferase 1; E/A: early/late diastolic; EDP: end-diastolic pressure; EDV: end-diastolic volume; EDWT: end diastolic wall thickness; EF: ejection fraction; ENaC: epithelial sodium channel; ER: endoplasmic reticulum; ERS: endoplasmic reticulum stress; ESV: end-systolic volume; GRP78: glucose-regulated protein 78; HHF: heart failure hospitalization; HR: hazard ratio; I/R: ischemic/reperfusion; IRI: ischemic/reperfusion injury; LAD: left anterior descending artery; LV: left ventricular; LVES: left ventricular end-systolic pressure; LVESV: left ventricular end-systolic volume; MFF2: mitofusin 2; MI: myocardial infarction; NHE: Na\(^+\)/H\(^+\) exchanger; NLRP3: nucleotide-binding oligomerization domain-like receptor 3; OPA1: optic atrophy 1; PGC1-α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; RAGEs: receptors for advanced glycation end products; ROS: reactive oxygen and nitrogen species; RPP: relative pressure reduction; SERCA2a: sarcoplasmic endoplasmic reticulum Ca\(^{2+}\)-ATPase; SGLT1: sodium–glucose co-transporters; SGLT2: sodium–glucose co-transporters; STAT3: signal transducer and activator of the transcription 3; T2DM: type 2 diabetes mellitus; Tau: time constant for isovolumic relaxation; TRAF2: tumor necrosis factor receptor-associated factor 2; XBP1: X-box binding protein 1.

Authors’ contributions

All authors wrote, revised and approved the manuscript. All authors read and approved the final manuscript.

Author details

1 Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 2 Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3 Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand. 4 Center of Excellence Award (NC). This work was supported by the Thailand Research Fund Grant RTA6080003 (SCC), the NSTDA Research Chair Grant from the National Science and Technology Development Agency Thailand (NC), and the Chiang Mai University Center of Excellence Award (NC).

References

1. Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini review. Curr Diab Rev. 2017;13:3–10.
2. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the american heart association. Circulation. 2016;133:447–54.
4. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142:375–415.
5. Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin. 2012;8:619–31.
6. González-Vilchez F, Ayuela J, Ares M, Pi J, Castillo L, Martín-Durán R. Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol. 2005;101:53–8.
7. Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci Lond Engl. 1979;17(131):897–915.
8. Ferrannini E. Sodium–glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26:27–38.
9. Vrbová I, Balen Eror D, Klessen D, Burger C, Brejjak D, Kraus O, et al. Localizations of Na(+)-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881–98.
10. Verbrugge FH. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure. Curr Heart Fail Rep. 2017;14:275–83.
11. Tomlinson B, Hu M, Zhang Y, Chan P, Liu Z-M. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2017;13:211–23.
12. Zinman B, Wanner C, Lachin JM, Fitchett D, Buhlmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
13. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondo N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
14. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on...
55. Zhou L, Cryan EV, D’Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+-glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90:339–46.

56. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diab Ther. 2010;1:57–92.

57. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S.

58. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

59. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium-glucose co-transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.

60. Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233–46.

61. Liang J, Jiang J, Frank SJ. Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation. Endocrinology. 2000;141:3328–36.

62. Zhou Y, Wu W. The sodium–glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;41:2503–12.

63. Ye Y, Bajaj M, Yang H-C, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes; further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119–32.

64. Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattapakorn SC, et al. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018;236:69–84.

65. Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, Ameliorates Cardiovascular Injury and Cognitive Dysfunction in Obese and Type 2 Diabetic Mice. J Cell Physiol. 2013;21:561–72.

66. Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, et al. Effect of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119–32.

67. Huang C-C, Monte A, Cook JM, Kabir MS, Peterson KP. Zebrafish heart repolarization in people with Type 2 diabetes. Diab Med J Br Diab Assoc. 2017;34:1367–71.

68. Milson J, Bengtsson E, Fredrikson GN, Björkbacka H. Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol. 2008;19:519–24.

69. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373–9.

70. Dixit VD. Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant? Diabetes. 2013;62:22–4.

71. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.

72. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11:897–904.

73. Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194–204.

74. Fuentes-Antráis J, Ioan AM, Tuhón J, Egido J, Lorenzo O. Activation of toll-like receptors and inflammasomes complexes in the diabetic cardiovascular-amyopathy-associated inflammation. Int J Endocrinol. 2014;2014:847827.

75. Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. Cardiovasc Diabetol. 2014;13:40.

76. Singh LP. The NLRP3 inflammasome and diabetic cardiomyopathy—editorial to “Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model” by Beibei Luo et al. Cardiovasc Drugs Ther. 2014;28.5–3.

77. Griending KK, Soresscu D, Ushio-Fukai M. NADPH oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501.

78. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertens Dallas Tex. 1997;2009(49):241–8.

79. Yamamoto E, Lai Z-F, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, et al. Enhancement of cardiovascular oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:2507–69.

80. Oelze M, Kroeller-Schön S, Welschf P, Jansen T, Hausding M, Mikheed Y, et al. The sodium–glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9:e112394.

81. Wang T, Mao X, Li H, Qiao S, Xu A, Wang J, et al. N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adipopectin and attenuated myocardial postischemic injury in diabetes. Free Radic Biol Med. 2013;63:291–303.

82. Jadhav A, Tiwari S, Lee P, Nilsang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage–M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2013;345:239–49.

83. Xia P, Liu Y, Cheng Z. Signaling pathways in cardiac myocyte apoptosis. Biomed Res Int. 2016;2016:9583268.

84. Takemura G, Kanoh M, Minatoguchi S, Fujiwara H. Cardiomyocyte apoptosis in the failing heart—a critical review from definition and classification of cell death. Int J Cardiol. 2013;167:2373–86.

85. Takemura G, Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med. 2006;10:56–75.

86. Liu Z-W, Zhu H-T, Chen K-L, Dong X, Wei J, Qu C, et al. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:158.

87. Saezegzi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7:880–5.

88. Ji Y, Zhao Z, Cai T, Yang P, Cheng M. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway. Mol Med Rep. 2014;9:1254–8.

89. Wu T, Dong Z, Geng J, Sun Y, Liu G, Kang W, et al. Valsalpan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci Off Eur J Pharmacol. 2011;43:496–502.

90. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107:881–91.

91. Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol. 2006;18:444–52.

92. Tong Q, Wu L, Jiang T, Ou Z, Zhang Y, Zhu D. Inhibition of endoplasmic reticulum stress-activated IRE1α-TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson’s disease. J Eur Pharm Sci. 2011;42:496–502.

93. Sari FR, Wydyanoto B, Thandavarayan RA, Harima M, Lakshmanan AP, Zhang S, et al. Attenuation of CHOP-mediated myocardial apoptosis...
in pressure-overloaded dominant negative p38α mitogen-activated protein kinase mice. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2011;27:487–96.

98. Cong X-Q, Piao M-H, Li Y, Xie L, Liu Y. Bis(maltolato)oxovanadium(IV) (BMOV) attenuates apoptosis in high glucose-treated cardiac cells and diabetic rat hearts by regulating the unfolded protein responses (UPRs). Biol Trace Elem Res. 2016;173:90–8.

99. Hernández-Reséndiz S, Buelna-Chontal M, Correa F, Zazueta C. Targeting mitochondria for cardiac protection. Curr Drug Targets. 2013;14:586–600.

100. Galloway CA, Yoon Y. Mitochondrial dynamics in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22:1545–62.

101. Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014;130:554–64.

102. Lucas E, Vila-Bedmar R, Arcones AC, Cruces-Sande M, Cachofeiro V, Mayor F, et al. Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. Cardiovasc Diabetol. 2016;15:155.

103. Duncan JC. Peroxisome proliferator activated receptor-alpha (PPARα) and PPAR gamma coactivator-1alpha (PGC-1α) regulation of cardiac metabolism in diabetes. Pediatr Cardiol. 2011;32:323–8.

104. Westermann B. Mitochondrial fusion and fission in cell life and death. Biochem Soc Trans. 2015;43:e38–47.

105. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062–5.

106. Ong S-B, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)−H(+)−exchanger in rats and rabbits. Diabetologia. 2017;60:568–73.

107. Liu T, O'Rourke B. Enhancing mitochondrial Ca(2+) uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res. 2010;103:279–88.

108. Kho C, Lee A, Hajar RJ. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. Nat Rev Cardiol. 2012;9:717–33.

109. Kawase Y, Hajar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5:554–65.

110. Park SH, Khemaisi-Benkhait S, Idris-Khodja N, Amoura L, Abbas M, Auger C, et al. Upregulation of sodium–glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats. Arch Cardiovasc Dis Suppl. 2018;10:224.

111. Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intragranular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogeneis. Cardiovasc Res. 2003;57:887–96.

112. Lambert R, Sodolski S, Peng X, Margules KE, Despa F, Despa S. Intracellular Na(+) concentration ([Na(+)]) is elevated in diabetic hearts due to enhanced Na(+)−glucose cotransport. J Am Heart Assoc. 2015;4:e002183.

113. Liu T, Takimoto E, Dimaano VL, DelMazumder D, Kettlewell S, Smith G, et al. Inhibiting mitochondrial Na(+)−Ca(2+) exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res. 2014;115:44–54.

114. Baartscheer A, Hardzyenka M, Schumacher CA, Belterman CNW, van Boren MMGJ, Verkerk AQ, et al. Chronic inhibition of the Na(+)−H(+)−exchanger causes regression of hypertrophy, heart failure, and sonic and electrophysiological remodelling. Br J Pharmacol. 2008;154:1266–75.

115. Baartscheer A, Schumacher CA, van Boren MMGJ, Belterman CNW, Coronel R, Ophoff T, et al. Chronic inhibition of Na(+)−H(+)−exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res. 2005;65:83–92.

116. Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)−H(+)−exchanger in rats and rabbits. Diabetologia. 2017;60:568–73.

117. Liu T, O'Rourke B. Enhancing mitochondrial Ca(2+) uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res. 2010;103:279–88.

118. Kho C, Lee A, Hajar RJ. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. Nat Rev Cardiol. 2012;9:717–33.

119. Kawase Y, Hajar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5:554–65.

120. Park SH, Khemaisi-Benkhait S, Idris-Khodja N, Amoura L, Abbas M, Auger C, et al. Upregulation of sodium–glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats. Arch Cardiovasc Dis Suppl. 2018;10:224.

121. Han Y, Cho Y-E, Ayon R, Guo R, Youssif KD, Pan M, et al. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1027–36.

122. Leng W, Ouyang X, Lei X, Wu M, Chen L, Wu Q, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− mice. Mediators Inflamm. 2016;2016:6305735.